Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
Digestive Disease Week 2022
2022 ASCO Annual Meeting
2022 American Society of Breast Surgeons Annual Meeting
2022 Community Oncology Alliance Annual Meeting
ESMO Breast Cancer Congress 2022
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.
Showing All Recent Newsreels Videos
Select Meeting
Toggle Dropdown
2021 ASCO Annual Meeting
AACR Annual Meeting 2021
SGO 2021 Virtual Annual Meeting on Womens Cancer
NCCN 2021 Virtual Annual Conference
Quick Chats
View all
Advertisement
AACR Annual Meeting 2022
John B.A.G. Haanen, MD, PhD, on Solid Tumors: Early Study Results on CAR T Cells and the CARVac Vaccine Strategy
Yaqi Zhao, MSc, on ALL: Molecular Profile and Efficacy of Inotuzumab Ozogamicin
Alana L. Welm, PhD, on Metastatic Outgrowth in the Lungs: Identifying a New Immune-Mediated Pathway
Josh Neman, PhD, on Brain Metastasis: A Neuroscience Perspective
Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin
Vivek Subbiah, MD, on Designing Clinical Trials for Precision Oncology
Ari M. VanderWalde, MD, MPH, MBioeth, on Melanoma: New Data on Ipilimumab and Nivolumab
Klaus Pantel, MD, on Liquid Biopsy Research: Opportunities and Challenges
Patricia M. LoRusso, DO, on Targeting KRAS: Clinical Successes and Challenges
Tina Cascone, MD, PhD, on NSCLC: New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy
Silvia C. Formenti, MD, on Adapting Radiation Therapy to Immune Checkpoint Blockade
Iván Márquez-Rodas, MD, PhD, on Advanced Melanoma: Efficacy of Intratumoral BO-112 With Systemic Pembrolizumab
Meenakshi Anurag, PhD, on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant
Electra D. Paskett, PhD, on Social Stresses and Cancer Treatment: An Expert Perspective
Maria Elena Martinez, PhD, MPH, on Colorectal Cancer Screening in Underserved Populations: COVID, Silver Linings, and Challenges Ahead
Nicolas Girard, MD, PhD, on NSCLC: New Data on Event-Free Survival With Nivolumab Plus Platinum-Doublet Chemotherapy
Gautam Mehta, MD, on Precision Oncology: An Overview of the Accelerated Approval Program
Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease
David A. Barbie, MD, on Mesothelioma: Activating the STING Pathway May Promote Antitumor Immunity
Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy
Cheryl L. Willman, MD, on Cancer Genomic Sequencing in Tribal Nations of the American Southwest
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials
Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305
Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications
Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research
Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution
Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges
Matthew L. Meyerson, MD, PhD, on Lung Adenocarcinoma: Somatic Mutations, Germline Risk, and Ancestry
NCCN 2022 Annual Conference
Julio M. Pow-Sang, MD, on Nonmetastatic Prostate Cancer: Update on Best Management Practices
Margaret A. Tempero, MD, on Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options
Thomas W. Flaig, MD, on Bladder Cancer: New Treatment Options
Reid M. Ness, MD, MPH, on Colorectal Cancer: Updates in Screening Recommendations
Genevieve Boland, MD, PhD, on Advanced Melanoma: Best Management Practices
Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates
Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors
Smitha S. Krishnamurthi, MD, on Colorectal Cancer: Treatment Updates
SGO 2022 Annual Meeting on Women’s Cancer
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine
Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery
2022 Multidisciplinary Head and Neck Cancers Symposium
Phillip Pifer, MD, PhD, on Head and Neck Squamous Cell Carcinoma: New Data on Focal Adhesion Kinase
Glenn J. Hanna, MD, on Oropharyngeal Squamous Cell Carcinoma: Detecting Occult Recurrence
Nancy Lee, MD: Toward Personalization of Radiotherapy for HPV-Related Oropharyngeal Carcinoma
Peter Zeng, MD/PhD Candidate: Immune Cell Signature Predicts Survival in HPV-Associated Head and Neck Cancer
David S. Hong, MD, on New Findings on Tisotumab Vedotin-tftv in Patients With Head and Neck Squamous Cell Carcinoma
Michelle Mierzwa, MD, on Oropharyngeal Cancer: Early Results on De-escalated Radiotherapy
Elizabeth D. Cash, PhD, on Addressing the Psychological Aspects of Head and Neck Cancer
Sue S. Yom, MD, PhD, on Thyroid Cancer: Expert Perspective on the State of the Field
2022 ASCO Genitourinary Cancers Symposium
Matthew R. Zibelman, MD, on Renal Cell Carcinoma: New Results on Combination of Nivolumab and Axitinib
Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy
Alfredo Berruti, MD, on Adrenocortical Carcinoma: Preliminary Study Results With Adjuvant Mitotane
Daniel P. Petrylak, MD, on Bladder Cancer: Study EV-103 Cohort H Findings on Enfortumab Vedotin-ejfv
Axel Bex, MD, PhD, on Renal Cell Carcinoma: New Findings From the NeoAvAx Trial on Avelumab and Axitinib
Fred Saad, MD, on Prostate Cancer: Results From the PROpel Trial on Olaparib and Abiraterone
Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone
Simon J. Crabb, PhD, MBBS, on Urothelial Carcinoma: Switch Maintenance Therapy With Rucaparib Following Chemotherapy
Wesley Yip, MD, on Urothelial Carcinoma: New Data on Neoadjuvant Gemcitabine and Cisplatin
Karen E. Knudsen, PhD, MBA, on Addressing Disparities in Genitourinary Cancers
Karim Fizazi, MD, PhD, on Prostate Cancer: Early Results From the CYPIDES Trial of ODM-208
Kim Nguyen Chi, MD, on Prostate Cancer: New Findings on Niraparib, Abiraterone, and Prednisone
Jonathan E. Rosenberg, MD, on Urothelial Cancer: New Conclusions About Durvalumab Plus Olaparib
Toni K. Choueiri, MD, on Renal Cell Carcinoma: Follow-up Data on Pembrolizumab
Massimo Di Maio, MD, on Urothelial Cancer: Data on Niraparib and Best Supportive Care as Maintenance Therapy
Alicia K. Morgans, MD, MPH, on Prostate Cancer: Profiles of Patients and Their Journeys
Petros Grivas, MD, PhD, on Urothelial Cancer: New Data on Sacituzumab Govitecan-hziy and Pembrolizumab
Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective
Neil E. Fleshner, MD, MPH, on High-Risk Prostate Cancer: New Data on Abiraterone and Cabazitaxel
Tanya B. Dorff, MD, on Prostate Cancer: Early Data on PSCA-Targeted CAR T-Cell Therapy
Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide
Matthew R. Smith, PhD, MD, on Prostate Cancer: Phase III Data on Darolutamide, Androgen Deprivation, and Docetaxel
2021 Multidisciplinary Thoracic Cancers Symposium
Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers
Carolyn Presley, MD, on Dementia in Patients Treated for Thoracic Cancer
Pranshu Mohindra, MD, MBBS, on NSCLC: Benefits of Intensity-Modulated Proton Therapy–Based Reirradiation
Mirek Fatyga, PhD, on NSCLC: New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy
Narjust Duma, MD, on Advanced NSCLC: Reducing Racial Disparities in Outcomes
Ara Klijian, MD, on Lung Cancer: Operability in Patients With Poor Pulmonary Function
2022 ASCO Gastrointestinal Cancers Symposium
Kohei Shitara, MD, on Gastric and Esophageal Cancers: Long-Term Follow-up on Nivolumab Plus Chemotherapy
Yu Sunakawa, MD, PhD, on Gastric Cancer: Predicting Treatment-Related Toxicities With Biomarkers
Heinz-Josef Lenz, MD, on Colorectal Cancer: Update From the CheckMate 9X8 Trial on Nivolumab, mFOLFOX6, and Bevacizumab
Nilofer Saba Azad, MD, on Novel Treatment Combinations Under Study in Biliary Tract Cancers
Ghassan K. Abou-Alfa, MD, MBA, on Hepatocellular Carcinoma: Open-Label Trial of Tremelimumab and Durvalumab
Tanios S. Bekaii-Saab, MD, on Pancreatic and Other Tumors With KRAS G12C Mutation: Updated Data on Use of Adagrasib
Afsaneh Barzi, MD, PhD, on Colorectal Cancer: Early Data on Regorafenib and Pembrolizumab
Zev A. Wainberg, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Follow-up Data on Pembrolizumab and Chemotherapy
Francesca Battaglin, MD, on Upper GI Cancers and the Potential Value of Recurrent Neoantigens
Anthony B. El-Khoueiry, MD, on Hepatocellular Carcinoma: Expert Perspective on Novel Additive Strategies
Gabriel A. Brooks, MPH, MD, on Colorectal Cancer: Expert Perspective on the Need to Deintensify Oxaliplatin
Van K. Morris, MD, on Metastatic Colorectal Cancer: Early Trial Results on Encorafenib, Cetuximab, and Nivolumab
Melissa Amy Lumish, MD, on Rectal Cancer: PD-1 Blockade for Mismatch Repair–Deficient Disease
Romain Cohen, MD, PhD, on Metastatic Colorectal Cancer: Long-Term Follow-up on Nivolumab Plus Ipilimumab
Thierry André, MD, on Esophagogastric Adenocarcinoma: New Findings on Nivolumab and Ipilimumab
2021 ASH Annual Meeting & Exposition
Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax
L. Elizabeth Budde, MD, PhD, on Relapsed/Refractory Follicular Lymphoma: Early Results on Mosunetuzumab Monotherapy
Daniel A. Ermann, MD, on DLBCL: Outcomes With Consolidative Radiation Therapy
Talha Badar, MD, on TP53-Mutated AML and the Impact of Allogeneic Stem Cell Transplantation on Survival
Tarek H. Mouhieddine, MD, on Relapsed/Refractory Multiple Myeloma and Bispecific Antibodies
Masayuki Umeda, MD, on Pediatric AML: Identifying a Key Subtype-Defining Lesion
Carsten Utoft Niemann, MD, PhD, on CLL: Time-Limited Venetoclax and Ibrutinib for Patients With Relapsed or Refractory Disease
Michael R. Bishop, MD, on Aggressive B-Cell NHL: Tisagenlecleucel vs Standard of Care as Second-Line Therapy
Roni Shouval, MD, PhD, on TP53-Mutant Large B-Cell Lymphoma and CAR T-Cell Therapy
Eunice S. Wang, MD, on FLT3-Mutated AML: Gilteritinib and Azacitidine for Intensive Induction Chemotherapy–Ineligible Patients
Leslie S. Kean, MD, PhD, on Bone Marrow Transplantation: Using Abatacept to Prevent Graft-vs-Host Disease
Alba Rodriguez-Meira, DPhil, on TP53-Mutated Leukemic Transformation in Myeloproliferative Neoplasms
Andrew Matthews, MD, on AML: CPX-351 vs Venetoclax/Azacitidine for Initial Therapy
Sangeetha Venugopal, MD, on Secondary AML: Impact of Front-Line Treatment Approach
Nikhil C. Munshi, MD, PhD, on COVID-19 Vaccine Effectiveness in Patients With Multiple Myeloma
Joe Schroers-Martin, MD, on Follicular Lymphoma: Precursor Mutations May Be Detectable Years Before Diagnosis
Manali Kamdar, MD, on Large B-Cell Lymphoma: Lisocabtagene Maraleucel vs the Standard of Care
Musa Yilmaz, MD, on FLT3-ITD–Mutated AML: Findings on Quizartinib With Decitabine and Venetoclax
Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma
Romanos Sklavenitis-Pistofidis, MD, on Smoldering Myeloma: Identifying Biomarkers of Response to Immunotherapy
Tycel Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib
Matthew S. Davids, MD, on Younger Patients With CLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy
2021 San Antonio Breast Cancer Symposium
Peter Schmid, MD, PhD, on Early-Stage Triple-Negative Breast Cancer: Neoadjuvant Treatment With Pembrolizumab and Chemotherapy
Kevin Kalinsky, MD, on HR-Positive HER2-Negative Breast Cancer: Endocrine Therapy and Chemotherapy
Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy
François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Endocrine Therapy and Palbociclib
Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment
Komal Jhaveri, MD, on Triple-Negative and Metastatic Breast Cancers: New Data on Neratinib, Fulvestrant, and Trastuzumab
Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life
Charles Coombes, MD, PhD, on Hormone Receptor–Positive HER2-Negative Breast Cancer: Use of Samuraciclib Plus Fulvestrant
Lisa A. Carey, MD, on HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies
Ann H. Partridge, MD, MPH, on SABCS Meeting Highlights: Expert Perspective
Banu Arun, MD, on Fine-Tuning Risk Assessment and Risk Reduction in Breast Cancer
Elizabeth A. Mittendorf, MD, PhD, on Making Strides in Managing Triple-Negative Breast Cancer
Meredith M. Regan, ScD, on Early Breast Cancer: Updated Results From the TEXT and SOFT Trials
Sara A. Hurvitz, MD, on HER2-Positive Metastatic Breast Cancer: T-DXd vs T-DM1
SITC 2021
Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments
Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages
Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade
Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study
Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel
Hannah E. Dzimitrowicz, MD, on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors
John M. Kirkwood, MD, on Melanoma: Early Study Results on Vidutolimod and Pembrolizumab
Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment
Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine
Patrick Hwu, MD, and Mary Dean, JD, CAE, on What’s Ahead for Cancer Immunology and SITC
Lynda Chin, MD, on the Landscape and Future of Digital Medicine
Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab
Yevgeniy R. Semenov, MD, on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors
NCCN 2021 Virtual Congress: Hematologic Malignancies
Alice S. Mims, MD, on AML: Updates on Managing Newly Diagnosed Disease
Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines
2021 ASTRO Annual Meeting
Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy
Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study
David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery
Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Treatment-Related Cardiotoxicity
Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer
C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers
Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy
Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression
Mark K. Buyyounouski, MD, MS, on Prostate Cancer: Hypofractionated vs Conventional Radiotherapy After Surgery
Karen M. Winkfield, MD, PhD, on Digital Health to Improve Patient Outcomes and Experience
Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers
Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy
Erin Murphy, MD, on Low-Grade Glioma: Neurocognitive Function Following Treatment
Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT
Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases
Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective
Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial
2021 ASCO Quality Care Symposium
Tina Shih, PhD, on Trends in Total and Out-of-Pocket Costs of Cancer Care
Manali I. Patel, MD, MPH, on Community-Based Intervention and Cancer Care Disparity
Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery
Sarah S. Mougalian, MD, on a Next-Day Access Program for Patients With Cancer
Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology
Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence
Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide
Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients
John V. Cox, DO, MBA, on Reshaping Practice Models to Better Care for Patients With Cancer
Jenny Jing Xiang, MD, on Improving Clinical Trial Recruitment With a Universal Prescreening Protocol
Aakash Desai, MPH, MD, on the Precision Oncology Promise: Can We Deliver?
Katherine E. Reeder-Hayes, MD, MBA, on Geography, Breast Cancer Treatment, and Racial Disparities
Morgan R.L. Lichtenstein, MD, on Insurance Plan, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs
ESMO Congress 2021
Helena M. Earl, MBBS, PhD, on HER2-Positive Early Breast Cancer: A Meta-analysis of Trastuzumab Trials
Nicoletta Colombo, MD, on Cervical Cancer: KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy
Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Jason J. Luke, MD, on Melanoma: KEYNOTE-716 Trial of Pembrolizumab vs Placebo
Gabriel N. Hortobagyi, MD, on Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib
Toni K. Choueiri, MD, on Renal Cell Carcinoma: Quality-of-Life Data From KEYNOTE-564 on Pembrolizumab vs Placebo
Naveen S. Vasudev, PhD, MBChB, on RCC: Changing the Dosing Schedule of Ipilimumab Plus Nivolumab
Gerhardt Attard, MD, PhD, on Prostate Cancer: Abiraterone and Prednisolone in the STAMPEDE Protocol
Karim Fizazi, MD, PhD, on Prostate Cancer: Newly Reported Survival Rates With Abiraterone, Docetaxel, and Prednisone
Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease
Robin Cornelissen, MD, PhD, on HER2 Exon 20–Mutated NSCLC: Poziotinib in Treatment-Naive Disease
Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring
Jonathan Lim, MBBS, MRCP: The Future of the Oncology Workforce Since the COVID-19 Pandemic
Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials
Thomas Powles, MD, PhD, on Urothelial Carcinoma: Erdafitinib, Cetrelimab, and FGFR Alterations
Neeraj Agarwal, MD, on Advanced Prostate Cancer: Data on Cabozantinib Plus Atezolizumab
Filippo Pietrantonio, MD, and Federica Morano, MD, on Colorectal Cancer and the MAYA Trial Strategy: Temozolomide, Ipilimumab, and Nivolumab
Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial
Susana N. Banerjee, MBBS, PhD, on Ovarian, Fallopian Tube, or Primary Peritoneal Adenocarcinoma: Treatment Findings From the EORTC-1508 Trial
Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Novel Combination Therapy Under Study
Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Treatment Findings From KEYNOTE-355 on Pembrolizumab and Chemotherapy
SOHO 2021
Curtis Lachowiez, MD, on AML: Venetoclax Combined With FLAG-IDA
Saad Z. Usmani, MBA, MD, on Multiple Myeloma: Updated Results From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma
Luis E. Aguirre, MD, on Chronic Myelomonocytic Leukemia: Keys to Assessment and Treatment
IASLC 2021 World Conference on Lung Cancer
Matthew Smeltzer, PhD, on International Lung Cancer Clinical Trials: The Impact of COVID-19
Alex A. Adjei, MD, PhD, on Disparities in Lung Cancer Care: The Global Burden
Christine D. Berg, MD, on Lung Cancer Deaths Attributable to Air Pollution: Global Variability
Jamie L. Studts, PhD, on The Stigma of Lung Cancer: It’s Time to Eliminate It
Prasad S. Adusumilli, MD, on CAR T-Cell Therapy for Mesothelioma
Nasser K. Altorki, MD, on NSCLC: Adjuvant Atezolizumab for Stage IB–IIIA Disease
2021 Pan Pacific Lymphoma Conference
Peihua (Peggy) Lu, MD, on CAR T-Cell Therapy: Research in China
David S. Kroll, MD, on Recognizing and Treating Depression and Anxiety in Patients With Lymphoma
Jared E. Matya, PharmD, BCOP, on Supportive Therapies for Side Effects Related to Novel Oral Treatments
Andrew D. Zelenetz, MD, PhD, on MRD Testing in the Management of Non-Hodgkin Lymphoma
Jonathan W. Friedberg, MD, on Managing Indolent NHL With Oral Therapies
Alexey V. Danilov, MD, PhD, on Lymphoid Malignancies: Novel Agents Targeting BTK Inhibitor–Resistant Disease
Alison J. Moskowitz, MD, on ABVD in Hodgkin Lymphoma: Adding Brentuximab Vedotin and Checkpoint Inhibitors to Standard Treatment
Bruce D. Cheson, MD, and Stephen M. Ansell, MD, PhD, on Non-Hodgkin and Follicular Lymphomas: Integrating Non–CAR T-Based Treatments
Sonali M. Smith, MD: Can CNS Prophylaxis Prevent Secondary High-Grade B-Cell Lymphomas?
James O. Armitage, MD, on Advanced Hodgkin Lymphoma: Choosing Among BEACOPP, A-AVD, and Checkpoint Inhibitors
Steven M. Horwitz, MD, on Advanced-Stage Mycosis Fungoides and Sezary Syndrome: Update on Management Practices
Nina Shah, MD, on Newly Diagnosed Multiple Myeloma: Novel Combination Therapies
Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies
EHA 2021 Virtual Congress
Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab
Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response
Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab
Gaurav Goyal, MD, on DLBCL: Comparing R-CHOP and R-EPOCH for Overall Survival Benefits
Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy
Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation
Martin Hutchings, MD, PhD, on Hodgkin Lymphoma: Brentuximab Vedotin With Chemotherapy
Claire Harrison, MD, DM, on Myelofibrosis: Fedratinib as First-Line Therapy After Prior Ruxolitinib
Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib
Cristina Gasparetto, MD, on Multiple Myeloma: Selinexor, Carfilzomib, and Dexamethasone in Carfilzomib-Nonrefractory Patients
Martin H. Dreyling, MD, PhD, on Follicular Lymphoma: Safety and Efficacy of Tisagenlecleucel
Advertisement
Advertisement
May
27
Today In Oncology
Race/Ethnicity and Poverty Are Associated With Worse Outcomes Among Children With High-Risk Neuroblastoma
Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer
Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic, but Varied by Race, Socioeconomic Status, and Other Factors
Multiple Myeloma: Treatment Conundrums
View More
Advertisement